Related Experiment Video
Updated: Mar 6, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis
Daisuke Koshiyama1, Kenji Kirihara1, Mariko Tada1
1Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abstract:
The auditory mismatch negativity (MMN) is a component of event-related potentials, which is being increasingly recognized as a candidate biomarker for early stages of psychosis. Although previous cross-sectional studies have demonstrated small MMN amplitude in early stages of psychosis, it remains unknown whether small MMN amplitude is due to progressive reduction during the early course. In this study, we investigated longitudinal changes of MMN in early stages of psychosis. Participant included 14 patients with first-episode psychosis (FEP), 16 individuals with ultra-high risk (UHR), and 16 healthy control subjects (HC). We measured MMN in response to duration deviants (dMMN) and that in response to frequency deviants (fMMN), respectively. The amplitudes of dMMN in FEP and UHR were significantly smaller in comparison to those in HC, which did not show a progressive decrease over time. The amplitude of fMMN did not differ among groups, which again did not show progression. There was no significant correlation between the length of the follow-up period and the longitudinal change of either deviant-type MMN in the FEP or UHR. These results suggest that dMMN is a trait marker in the early stages of psychosis, and that small dMMN amplitude in early stages of psychosis may reflect altered developmental process rather than progressive brain pathology. The amplitude of fMMN may not alter in early stages of psychosis. These findings may contribute to the future establishment of MMN as a biomarker in early stages of psychosis.
Insights
Auditory mismatch negativity (MMN) is a potential biomarker for early psychosis. This study found smaller MMN amplitudes in individuals at high risk or with first-episode psychosis, suggesting a developmental trait rather than progressive decline.
Area of Science:
- Neuroscience
- Psychiatry
- Biomarkers
Background:
- Auditory mismatch negativity (MMN), an event-related potential, is a candidate biomarker for early psychosis.
- Previous studies show reduced MMN amplitude in early psychosis, but longitudinal changes are unclear.
Purpose of the Study:
- To investigate longitudinal changes in MMN amplitude in individuals with first-episode psychosis (FEP) and ultra-high risk (UHR) for psychosis.
- To determine if reduced MMN amplitude reflects progressive pathology or a stable trait.
Main Methods:
- Longitudinal MMN assessment in 14 FEP patients, 16 UHR individuals, and 16 healthy controls (HC).
- MMN measured for duration deviants (dMMN) and frequency deviants (fMMN).
- Analysis of MMN amplitude changes over the follow-up period.
Main Results:
- Significantly smaller dMMN amplitudes were observed in FEP and UHR groups compared to HC.
- dMMN amplitude did not show progressive decrease over time in FEP or UHR groups.
- fMMN amplitude did not differ between groups and showed no progression.
Conclusions:
- Reduced dMMN amplitude in early psychosis may represent a stable trait, possibly linked to altered developmental processes.
- fMMN amplitude appears unaffected in the early stages of psychosis.
- These findings support dMMN's potential as a biomarker for early psychosis stages.
Related Concept Videos
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Psychosis: Goals of Pharmacotherapy

